Navigation Links
JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
Date:7/5/2011

PARSIPPANY, N.J., July 5, 2011 /PRNewswire/ -- JHP Pharmaceuticals, a leading marketer and manufacturer of sterile injectable products, is launching larger pack sizes for three products commonly used in acute care clinical settings: Adrenalin® (epinephrine injection, USP), Coly-Mycin® M Parenteral (colistimethate sodium, USP) and Pitocin® (oxytocin injection, USP synthetic).

Stuart Hinchen, CEO and President of JHP noted, "The larger pack size was developed to meet customer demand for cost savings and increased pharmacy efficiency by reducing packaging waste.  Our new multipacks allow pharmacy staff to open one carton containing multiple vials rather than open multiple cartons containing only one vial.  The efficiency is critical in busy pharmacies handling high volume products such as Adrenalin®, Coly-Mycin® M and Pitocin® and the cost savings are significant."  

Commenting on JHP's philosophy of marketing mature brand name products at competitive prices, Hinchen stated, "JHP is focused on meeting three key customer needs: quality, price and supply.  Reducing packaging waste in high volume products is an example of how we stay price competitive without sacrificing quality.  We are also vigilant in our efforts to provide the market with a reliable drug supply.  Since we manufacture our products, we have the dexterity to adapt to changing market demand which is crucial in today's injectable market."

All three products are still available in single vial packs to meet the needs of smaller clinical settings.  For more information about these products or other JHP products, please visit www.jhppharma.com/jhppricing and contact your local wholesaler or distributor.Products Available in a New Multipack Size* NDCProductStrengthVial SizePackSizeLatexFree42023-101-10Adrenalin® Injection1mg/mL30mL MDV10Yes42023-107-06Coly-Mycin® M Parenteral 150mg colistin base10mL SDV6Yes42023-116-02Pitocin® 10 units/mL10mL MDV25Yes*See full prescribing information for JHP products at http://www.jhppharma.com/products/About JHP Pharmaceuticals, LLC - JHP Pharmaceuticals, headquartered in New Jersey, is an integrated specialty healthcare company that acquires, develops, manufactures and sells sterile injectable products.  JHP markets 15 well-established branded pharmaceutical products primarily into the hospital segment.  JHP provides customers with a reliable supply of brand name products at competitive prices. 

JHP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas.  For more information, please visit www.jhppharma.com.

Contact:JHP Customer Service Tel: 1-877-547-4547MK246B
'/>"/>

SOURCE JHP Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):